162.33 USD
-5.6 (-3.33%)
162.33 USD
0 (0%)
RGEN gets a fundamental rating of 5 out of 10. The analysis compared the fundamentals against 58 industry peers in the Life Sciences Tools & Services industry. While RGEN has a great health rating, its profitability is only average at the moment. RGEN is valied quite expensively at the moment, while it does show a decent growth rate.
1. Profitability
1.1 Basic Checks
- In the past year RGEN was profitable.
- In the past year RGEN had a positive cash flow from operations.
- RGEN had positive earnings in 4 of the past 5 years.
- Each year in the past 5 years RGEN had a positive operating cash flow.
1.2 Ratios
- RGEN has a better Return On Assets (0.06%) than 68.42% of its industry peers.
- RGEN's Return On Equity of 0.08% is fine compared to the rest of the industry. RGEN outperforms 70.18% of its industry peers.
- RGEN has a Return On Invested Capital (1.05%) which is comparable to the rest of the industry.
- Measured over the past 3 years, the Average Return On Invested Capital for RGEN is significantly below the industry average of 13.29%.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| ROA | 0.06% | ||
| ROE | 0.08% | ||
| ROIC | 1.05% |
ROA(3y)2.57%
ROA(5y)3.26%
ROE(3y)3.42%
ROE(5y)4.3%
ROIC(3y)2.65%
ROIC(5y)3.3%
1.3 Margins
- RGEN has a better Profit Margin (0.25%) than 68.42% of its industry peers.
- RGEN has a Operating Margin of 6.58%. This is in the better half of the industry: RGEN outperforms 63.16% of its industry peers.
- In the last couple of years the Operating Margin of RGEN has declined.
- With a Gross Margin value of 51.59%, RGEN perfoms like the industry average, outperforming 59.65% of the companies in the same industry.
- RGEN's Gross Margin has declined in the last couple of years.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| OM | 6.58% | ||
| PM (TTM) | 0.25% | ||
| GM | 51.59% |
OM growth 3Y-58.46%
OM growth 5Y-32.3%
PM growth 3YN/A
PM growth 5YN/A
GM growth 3Y-4.88%
GM growth 5Y-2.12%
2. Health
2.1 Basic Checks
- RGEN has a Return on Invested Capital (ROIC), which is below the Cost of Capital (WACC), which means it is destroying value.
- The number of shares outstanding for RGEN has been increased compared to 1 year ago.
- RGEN has more shares outstanding than it did 5 years ago.
- Compared to 1 year ago, RGEN has an improved debt to assets ratio.
2.2 Solvency
- RGEN has an Altman-Z score of 7.42. This indicates that RGEN is financially healthy and has little risk of bankruptcy at the moment.
- Looking at the Altman-Z score, with a value of 7.42, RGEN belongs to the top of the industry, outperforming 85.96% of the companies in the same industry.
- The Debt to FCF ratio of RGEN is 5.05, which is a neutral value as it means it would take RGEN, 5.05 years of fcf income to pay off all of its debts.
- RGEN has a Debt to FCF ratio of 5.05. This is in the better half of the industry: RGEN outperforms 68.42% of its industry peers.
- A Debt/Equity ratio of 0.26 indicates that RGEN is not too dependend on debt financing.
- With a Debt to Equity ratio value of 0.26, RGEN perfoms like the industry average, outperforming 50.88% of the companies in the same industry.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Debt/Equity | 0.26 | ||
| Debt/FCF | 5.05 | ||
| Altman-Z | 7.42 |
ROIC/WACC0.1
WACC10.75%
2.3 Liquidity
- RGEN has a Current Ratio of 8.36. This indicates that RGEN is financially healthy and has no problem in meeting its short term obligations.
- RGEN has a Current ratio of 8.36. This is amongst the best in the industry. RGEN outperforms 91.23% of its industry peers.
- A Quick Ratio of 7.14 indicates that RGEN has no problem at all paying its short term obligations.
- Looking at the Quick ratio, with a value of 7.14, RGEN belongs to the top of the industry, outperforming 89.47% of the companies in the same industry.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Current Ratio | 8.36 | ||
| Quick Ratio | 7.14 |
3. Growth
3.1 Past
- RGEN shows a strong growth in Earnings Per Share. In the last year, the EPS has been growing by 21.17%, which is quite impressive.
- RGEN shows a small growth in Earnings Per Share. Measured over the last years, the EPS has been growing by 7.11% yearly.
- Looking at the last year, RGEN shows a decrease in Revenue. The Revenue has decreased by -8.54% in the last year.
- The Revenue has been growing by 18.62% on average over the past years. This is quite good.
EPS 1Y (TTM)21.17%
EPS 3Y-21.5%
EPS 5Y7.11%
EPS Q2Q%6.98%
Revenue 1Y (TTM)-8.54%
Revenue growth 3Y-1.83%
Revenue growth 5Y18.62%
Sales Q2Q%21.94%
3.2 Future
- The Earnings Per Share is expected to grow by 24.54% on average over the next years. This is a very strong growth
- RGEN is expected to show quite a strong growth in Revenue. In the coming years, the Revenue will grow by 15.92% yearly.
EPS Next Y14.84%
EPS Next 2Y19.33%
EPS Next 3Y22.24%
EPS Next 5Y24.54%
Revenue Next Year15.61%
Revenue Next 2Y14.01%
Revenue Next 3Y14.31%
Revenue Next 5Y15.92%
3.3 Evolution
- The EPS growth rate is accelerating: in the next years the growth will be better than in the last years.
- When comparing the Revenue growth rate of the last years to the growth rate of the upcoming years, we see that the growth is stable.
4. Valuation
4.1 Price/Earnings Ratio
- The Price/Earnings ratio is 97.79, which means the current valuation is very expensive for RGEN.
- RGEN's Price/Earnings ratio is in line with the industry average.
- RGEN's Price/Earnings ratio indicates a rather expensive valuation when compared to the S&P500 average which is at 27.21.
- The Price/Forward Earnings ratio is 77.02, which means the current valuation is very expensive for RGEN.
- The rest of the industry has a similar Price/Forward Earnings ratio as RGEN.
- When comparing the Price/Forward Earnings ratio of RGEN to the average of the S&P500 Index (25.98), we can say RGEN is valued expensively.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PE | 97.79 | ||
| Fwd PE | 77.02 |
4.2 Price Multiples
- The rest of the industry has a similar Enterprise Value to EBITDA ratio as RGEN.
- The rest of the industry has a similar Price/Free Cash Flow ratio as RGEN.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| P/FCF | 85.81 | ||
| EV/EBITDA | 80.44 |
4.3 Compensation for Growth
- The high PEG Ratio(NY), which compensates the Price/Earnings for growth, indicates an expensive valuation of the company.
- RGEN's earnings are expected to grow with 22.24% in the coming years. This may justify a more expensive valuation.
PEG (NY)6.59
PEG (5Y)13.76
EPS Next 2Y19.33%
EPS Next 3Y22.24%
5. Dividend
5.1 Amount
- No dividends for RGEN!.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Dividend Yield | 0% |
REPLIGEN CORP / RGEN FAQ
Can you provide the ChartMill fundamental rating for REPLIGEN CORP?
ChartMill assigns a fundamental rating of 5 / 10 to RGEN.
What is the valuation status for RGEN stock?
ChartMill assigns a valuation rating of 2 / 10 to REPLIGEN CORP (RGEN). This can be considered as Overvalued.
What is the profitability of RGEN stock?
REPLIGEN CORP (RGEN) has a profitability rating of 4 / 10.
What is the financial health of REPLIGEN CORP (RGEN) stock?
The financial health rating of REPLIGEN CORP (RGEN) is 7 / 10.
What is the earnings growth outlook for REPLIGEN CORP?
The Earnings per Share (EPS) of REPLIGEN CORP (RGEN) is expected to grow by 14.84% in the next year.